secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122244
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q3 net loss $30.5M; ADI-001 trial expanded to six autoimmune indications
--------------------------------------------------------------------------------

- Net loss of $30.5M ($0.34 per share) vs $49.9M ($1.16) in Q3 2023; cash $202.1M.
- ADI-001 Phase 1 now covers LN, SLE, SSc, IIM, SPS, AAV; preliminary LN data expected 1H25.
- FDA cleared IND amendment for ADI-001 in IIM and SPS in October 2024.
- ADI-270 granted Fast Track for metastatic/advanced ccRCC; Phase 1 enrollment planned in Q4 2024.
- Appointed Lloyd Klickstein, M.D., Ph.D. to Board of Directors in August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024122244/0000950170-24-122244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024122244/acet-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer